Neuphoria Therapeutics (NASDAQ:NEUP) Issues Quarterly Earnings Results, Beats Estimates By $0.47 EPS

Neuphoria Therapeutics (NASDAQ:NEUP) issued its quarterly earnings results on Friday. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.47, FiscalAI reports.

Neuphoria Therapeutics Stock Down 7.1%

Shares of Neuphoria Therapeutics stock traded down $0.36 during trading hours on Friday, hitting $4.73. 79,662 shares of the company’s stock traded hands, compared to its average volume of 28,729. The company has a market cap of $25.49 million, a PE ratio of -1.07 and a beta of 0.72. Neuphoria Therapeutics has a twelve month low of $3.64 and a twelve month high of $21.40. The stock has a 50 day simple moving average of $4.72 and a 200-day simple moving average of $4.38.

Institutional Investors Weigh In On Neuphoria Therapeutics

A number of institutional investors have recently modified their holdings of the business. Geode Capital Management LLC boosted its position in shares of Neuphoria Therapeutics by 33.3% during the fourth quarter. Geode Capital Management LLC now owns 17,303 shares of the company’s stock worth $67,000 after buying an additional 4,325 shares during the period. Persistent Asset Partners Ltd boosted its position in shares of Neuphoria Therapeutics by 173.1% during the fourth quarter. Persistent Asset Partners Ltd now owns 13,403 shares of the company’s stock worth $52,000 after buying an additional 8,495 shares during the period. Commonwealth Equity Services LLC acquired a new position in shares of Neuphoria Therapeutics during the fourth quarter worth approximately $43,000. XTX Topco Ltd acquired a new position in shares of Neuphoria Therapeutics during the fourth quarter worth approximately $47,000. Finally, Boothbay Fund Management LLC acquired a new position in shares of Neuphoria Therapeutics during the fourth quarter worth approximately $54,000. Institutional investors own 15.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on NEUP shares. HC Wainwright downgraded shares of Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research note on Thursday, January 22nd. Finally, Zacks Research raised Neuphoria Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 3rd. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $21.00.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.